CONCORD biomarker prediction for novel drug introduction to different cancer types.

about

CONCORD biomarker prediction for novel drug introduction to different cancer types.

Item

http://www.wikidata.org/entity/Q50128212

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

CONCORD biomarker prediction for novel drug introduction to different cancer types.

@en

CONCORD biomarker prediction for novel drug introduction to different cancer types.

@nl

type

Item

label

CONCORD biomarker prediction for novel drug introduction to different cancer types.

@en

CONCORD biomarker prediction for novel drug introduction to different cancer types.

@nl

prefLabel

CONCORD biomarker prediction for novel drug introduction to different cancer types.

@en

CONCORD biomarker prediction for novel drug introduction to different cancer types.

@nl

P1476

CONCORD biomarker prediction for novel drug introduction to different cancer types.

@en

P2093

Jae K Lee

http://www.w3.org/2001/XMLSchema#string

Patrick M Dillon

http://www.w3.org/2001/XMLSchema#string

Taesung Park

http://www.w3.org/2001/XMLSchema#string

Youngchul Kim

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer

Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot"

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Integrated genomic analyses of ovarian carcinoma

Stromal gene signatures in large-B-cell lymphomas

Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.

Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.

Erlotinib in previously treated non-small-cell lung cancer

P304

1091-1106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23124

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29416679

http://www.w3.org/2001/XMLSchema#string

P932

5787421

http://www.w3.org/2001/XMLSchema#string